The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
暂无分享,去创建一个
H. Salih | A. Steinle | F. Grünebach | M. Krusch | Julia Salih | Theresa Placke | J. Hilpert | T. Placke
暂无分享,去创建一个
H. Salih | A. Steinle | F. Grünebach | M. Krusch | Julia Salih | Theresa Placke | J. Hilpert | T. Placke